156 related articles for article (PubMed ID: 35218996)
1. Foveal Thickness Fluctuation in Anti-VEGF Treatment for Branch Retinal Vein Occlusion: A Long-term Study.
Nagasato D; Muraoka Y; Tanabe M; Nishigori N; Osaka R; Mitamura Y; Tabuchi H; Kadomoto S; Murakami T; Ooto S; Suzuma K; Tsujikawa A
Ophthalmol Retina; 2022 Jul; 6(7):567-574. PubMed ID: 35218996
[TBL] [Abstract][Full Text] [Related]
2. Foveal Thickness Fluctuations in Anti-VEGF Treatment for Central Retinal Vein Occlusion.
Nagasato D; Muraoka Y; Tanabe M; Nishigori N; Osaka R; Mitamura Y; Tabuchi H; Murakami T; Ooto S; Suzuma K; Tsujikawa A
Ophthalmol Sci; 2024; 4(2):100418. PubMed ID: 38146527
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
[TBL] [Abstract][Full Text] [Related]
4. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
[TBL] [Abstract][Full Text] [Related]
5. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.
Kang HM; Chung EJ; Kim YM; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2013 Feb; 251(2):501-8. PubMed ID: 22653439
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion.
Pidro A; Pidro A; Nadarevic-Vodencarevic A; Halilbasic M; Lepara O; Nisic F
Rom J Ophthalmol; 2022; 66(1):22-26. PubMed ID: 35531462
[No Abstract] [Full Text] [Related]
7. Macular dynamics and visual acuity prognosis in retinal vein occlusions - ways to connect.
Dărăbuș DM; Pac CP; Roşca C; Munteanu M
Rom J Ophthalmol; 2023; 67(3):312-324. PubMed ID: 37876516
[No Abstract] [Full Text] [Related]
8. Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients.
Roy R; Saurabh K; Ghose A; Chandrasekharan DP; Sharma P; Pal SS; Das S
Asia Pac J Ophthalmol (Phila); 2017; 6(3):261-265. PubMed ID: 28379652
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-VEGF results between non-ischemic branch retinal vein occlusion and ischemic branch retinal vein occlusion with early sector panretinal photocoagulation.
Akdemir SC; Gunay BO
J Fr Ophtalmol; 2022 Nov; 45(9):1042-1047. PubMed ID: 36127168
[TBL] [Abstract][Full Text] [Related]
10. Optical Coherence Tomography Biomarkers Predicting Visual Acuity Change after Intravitreal Bevacizumab Injections for Macular Edema Secondary to Branch Retinal Vein Occlusion.
Segal O; Yavnieli R; Mimouni M; Rabina G; Geffen N; Moisseiev E; Nemet AY
Ophthalmologica; 2022; 245(1):19-24. PubMed ID: 34510041
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
Braimah IZ; Agyabeng K; Amoaku WM
Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
14. Classification of good visual acuity over time in patients with branch retinal vein occlusion with macular edema using support vector machine.
Matsui Y; Imamura K; Ooka M; Chujo S; Mase Y; Matsubara H; Kawanaka H; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1501-1508. PubMed ID: 34773490
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.
Zhao L; Li B; Feng K; Han L; Ma Z; Liu Y
Curr Eye Res; 2015 Jul; 40(7):752-6. PubMed ID: 25330134
[TBL] [Abstract][Full Text] [Related]
17. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.
Kang JW; Lee H; Chung H; Kim HC
Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1413-21. PubMed ID: 24577742
[TBL] [Abstract][Full Text] [Related]
18. Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment.
Parodi MB; Iacono P; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1647-51. PubMed ID: 25382074
[TBL] [Abstract][Full Text] [Related]
19. Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.
Zhang Q; Hou Y; Cao X; Zhang R; Liu Y; Wei C; Wu C; Mei L; Zhang P
BMC Ophthalmol; 2021 Nov; 21(1):402. PubMed ID: 34809591
[TBL] [Abstract][Full Text] [Related]
20. Twenty-four-month results of intravitreal aflibercept for macular edema due to branch retinal vein occlusion.
Sakanishi Y; Yasuda K; Morita S; Mashimo K; Tamaki K; Sakuma T; Ebihara N
Jpn J Ophthalmol; 2021 Jan; 65(1):63-68. PubMed ID: 33179193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
